Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Sirota, P. Articles by Korczyn, A. D. Search for Related Content PubMed Citation Articles by Sirota, P. Articles by Korczyn, A. D. Neurotransmitters Other Neuropsychiatric Disorders Schizophrenia Spectrum Disorders Other Neuroleptics

Use of the Selective Serotonin 3 Receptor Antagonist Ondansetron in the Treatment of Neuroleptic-Induced Tardive Dyskinesia

OBJECTIVE: The authors examined the efficacy, tolerability, and safety of ondansetron, a selective serotonin 3 receptor antagonist, in patients with tardive dyskinesia. METHOD: Twenty patients with schizophrenia who had neuroleptic-induced tardive dyskinesia were given 12 mg/day of ondansetron for 12 weeks in an open-label study. RESULTS: Administration of ondansetron resulted in a statistically significant improvement in tardive dyskinesia and psychotic symptoms. CONCLUSIONS: Ondansetron may be an effective and safe therapy to control tardive dyskinesia and psychosis in patients with schizophrenia.

This article has been cited by other articles:

				R. Rizzo, S. Marino, M. Gulisano, and M. M. Robertson The Successful Use of Ondansetron in a Boy With Both Leukemia and Tourette Syndrome J Child Neurol, January 1, 2008; 23(1): 108 - 111. [Abstract] [PDF]

				L. E. Adler, E. M. Cawthra, K. A. Donovan, J. G. Harris, H. T. Nagamoto, A. Olincy, and M. C. Waldo Improved P50 Auditory Gating With Ondansetron in Medicated Schizophrenia Patients Am J Psychiatry, February 1, 2005; 162(2): 386 - 388. [Abstract] [Full Text] [PDF]

				M. V. Puig, N. Santana, P. Celada, G. Mengod, and F. Artigas In Vivo Excitation of GABA Interneurons in the Medial Prefrontal Cortex through 5-HT3 Receptors Cereb Cortex, December 1, 2004; 14(12): 1365 - 1375. [Abstract] [Full Text] [PDF]

				J. Melke, L. Westberg, S. Nilsson, M. Landen, H. Soderstrom, F. Baghaei, R. Rosmond, G. Holm, P. Bjorntorp, L.-G. Nilsson, et al. A Polymorphism in the Serotonin Receptor 3A (HTR3A) Gene and Its Association With Harm Avoidance in Women Arch Gen Psychiatry, October 1, 2003; 60(10): 1017 - 1023. [Abstract] [Full Text] [PDF]

				M. A. Richardson, M. L. Bevans, L. L. Read, H. M. Chao, J. D. Clelland, R. F. Suckow, T. J. Maher, and L. Citrome Efficacy of the Branched-Chain Amino Acids in the Treatment of Tardive Dyskinesia in Men Am J Psychiatry, June 1, 2003; 160(6): 1117 - 1124. [Abstract] [Full Text] [PDF]

				L. Calabrese and G. McEnany Ondansetron in the Treatment of Antidepressant-Induced Nausea Journal of the American Psychiatric Nurses Association, June 1, 2001; 7(3): 94 - 96. [PDF]

				D. F. ZULLINO, C. B. EAP, and P. VOIROL Ondansetron for Tardive Dyskinesia Am J Psychiatry, April 1, 2001; 158(4): 657-a - 658. [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 2000 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us